✦ LIBER ✦

An Anti-MUC1 Antibody−Calicheamicin Conjugate for Treatment of Solid Tumors. Choice of Linker and Overcoming Drug Resistance

✍ Scribed by Hamann, Philip R.; Hinman, Lois M.; Beyer, Carl F.; Greenberger, Lee M.; Lin, Clara; Lindh, Delores; Menendez, Ana T.; Wallace, Rosalyn; Durr, Frederick E.; Upeslacis, Janis

Book ID: 120557421
Publisher: American Chemical Society
Year: 2005
Tongue: English
Weight: 161 KB
Volume: 16
Category: Article
ISSN: 1043-1802
DOI: 10.1021/bc049795f

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An Anti-CD33 Antibody−Calicheamicin Conj

An Anti-CD33 Antibody−Calicheamicin Conjugate for Treatment of Acute Myeloid Leukemia. Choice of Linker

✍ Hamann, Philip R.; Hinman, Lois M.; Beyer, Carl F.; Lindh, Delores; Upeslacis, J 📂 Article 📅 2002 🏛 American Chemical Society 🌐 English ⚖ 87 KB

Anti-CD22-MCC-DM1: an antibody-drug conj

Anti-CD22-MCC-DM1: an antibody-drug conjugate with a stable linker for the treatment of non-Hodgkin's lymphoma

✍ Polson, A G; Williams, M; Gray, A M; Fuji, R N; Poon, K A; McBride, J; Raab, H; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 642 KB

Antibody-Drug Conjugates and Immunotoxin

Antibody-Drug Conjugates and Immunotoxins || The Preclinical and Clinical Evaluation of VB6-845: An Immunotoxin with a De-Immunized Payload for the Systemic Treatment of Solid Tumors

✍ Phillips, Gail Lewis 📂 Article 📅 2012 🏛 Springer New York 🌐 English ⚖ 488 KB

This volume gathers the leading research on antibody-drug conjugates and immunotoxins. Following a rigorous overview, the volume delves into focused sections on all aspects of ADCs and ITs from clinical development through to targeted therapeutic applications and the latest technologies.